Laser Treatment of Onychomycosis

Policy Number: 2.01.89
Origination: 11/2015
Last Review: 5/2017
Next Review: 11/2017

Policy
Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide coverage for Laser Treatment of Onychomycosis. This is considered investigational.

When Policy Topic is covered
n/a

When Policy Topic is not covered
Laser treatment of onychomycosis is considered investigational.

Description of Procedure or Service

<table>
<thead>
<tr>
<th>Populations</th>
<th>Interventions</th>
<th>Comparators</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Individuals: With onychomycosis</td>
<td>Interventions of interest are: Laser therapy</td>
<td>Comparators of interest are: Topical antifungal nail lacquer Oral antifungal therapy</td>
<td>Relevant outcomes include: Symptoms Change in disease status Medication use Treatment-related morbidity</td>
</tr>
</tbody>
</table>

Onychomycosis is a common fungal infection of the nail. Currently available treatments for onychomycosis, including systemic and topical antifungal medications, have relatively low efficacy and require a long course of treatment. Laser systems are proposed as another treatment option.

For individuals who have onychomycosis who receive treatment with laser therapy, the evidence includes small randomized controlled trials (RCTs). Relevant outcomes are symptoms, change in disease status, medication use, and treatment-related morbidity. Some of the available RCTs have reported improvements in clinical outcomes with laser treatment, but these trials have mixed results and methodologic limitations. Clinical and mycological outcomes sometimes differed in the trials, which may be due in part to lack of consistent blinding of outcome assessment. The published evidence to date does not permit determining whether laser treatment improves health outcomes in patients with onychomycosis. Additional well-designed, adequately powered, and well-conducted
RCTs are needed. The evidence is insufficient to determine the effects of the technology on health outcomes.

**Background**

Onychomycosis is a common chronic fungal infection of the nail. It is estimated to cause up to 50% of all nail disease and 33% of cutaneous fungal infections.\(^1\) The condition can affect toenails or fingernails but is more frequently found in toenails. Primary infectious agents include dermatophytes (eg, *Trichophyton* species), yeasts (eg, *Candida albicans*) and nondermatophytic molds. In temperate Western countries, infections are generally caused by dermatophytes.

Aging is the most common risk factor for onychomycosis, most likely due to decreased blood circulation, longer exposure to fungi, and slower nail growth. In addition, various medical conditions increase the risk of comorbid onychomycosis. These include diabetes, obesity, peripheral vascular disease, immunosuppression, and HIV infection. In certain populations, onychomycosis may lead to additional health problems. Although there is limited evidence of a causal link between onychomycosis and diabetic foot ulcers, at least 1 prospective study with diabetic patients found onychomycosis to be an independent predictor of foot ulcer.\(^2\)

Moreover, onychomycosis, especially more severe cases, may adversely impact quality of life. Patients with onychomycosis have reported pain, uncomfortable nail pressure, embarrassment and discomfort wearing shoes.\(^3,4\)

The diagnosis of onychomycosis can be confirmed by potassium hydroxide preparation, culture or histology. Treatments for onychomycosis include topical antifungals such as nail paints containing ciclopirox (ciclopiroxolamine) or amorolfine, and oral antifungals such as terbinafine and itraconazole. These generally have low to moderate efficacy and a high relapse rate. Topical antifungals and some long-available oral medications such as griseofulvin require a long course of treatment, which presents issues for patient compliance. Moreover, oral antifungal medications have been associated with adverse effects such as a risk of hepatotoxicity.

Several types of device-based therapies are under investigation for treatment of onychomycosis, including ultrasound, iontophoresis, photodynamic therapy, and laser systems. A potential advantage of lasers is that they have greater tissue penetration than antifungal medication and thus may be more effective at treating infection embedded within the nail. Another potential advantage is that laser treatments are provided in a clinical setting in only 1 or several sessions, and thus, long-term patient compliance is less of an issue than with medications.

Laser treatment of onychomycosis uses the principle of selective photothermolysis. This is defined as the precise targeting of a tissue using a specific wavelength of light. The premise is that light is absorbed into the target area and heat generated by that energy is sufficient to damage the target area while sparing the surrounding area. The aim of laser treatment of onychomycosis is to heat the nail bed to temperatures required to disrupt fungal growth (approximately 40°C–60°C) and at the same time avoid pain and necrosis to surrounding tissues.\(^5\)
Characteristics of laser systems used to treat onychomycosis are as follows.\(^5\)

**Wavelength:** Lasers are single-wavelength light sources. There needs to be sufficient tissue penetration to adequately treat nail fungus. The near-infrared spectrum tends to be used because this is the part of the spectrum that has maximum tissue penetrance in the dermis and epidermis and the nail plate is similar to the epidermis. To date, most laser systems for treating onychomycosis have been Neodymium yttrium aluminum garnet (Nd:YAG) lasers that are typically operated at 1064 nm; 940 to 1320 nm and 1440 nm wavelengths are also options.

**Pulse duration:** Pulses need to be short to avoid damage to the tissue surrounding the target area. For example, short-pulse systems have microsecond pulse durations and Q-switched lasers have nanosecond pulse durations.

**Repetition rate (frequency of laser pulses, in hertz):** Spot size to the diameter of the laser beam. For treating onychomycosis, laser spot sizes range from 1 to 10 nm.

**Fluence:** This refers to the amount of energy delivered into the area and is measured in J/cm\(^2\).

---

**Regulatory Status**

**Table 2. Select Laser Systems Approved for Temporary Increase of Clear Nail in Patients With Onychomycosis**

<table>
<thead>
<tr>
<th>Device</th>
<th>Manufacturer</th>
<th>Approved</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nd:YAG 1064-nm laser systems</td>
<td>PinPointe™ FootLaser™ PinPointe USA (acquired by NuvoLase 2011)</td>
<td>2010</td>
</tr>
<tr>
<td>GenesisPlus™</td>
<td>Cutera</td>
<td>2011</td>
</tr>
<tr>
<td>VariaBreeze™</td>
<td>CoolTouch</td>
<td>2011</td>
</tr>
<tr>
<td>JOULE ClearSense™</td>
<td>Sciton</td>
<td>2011</td>
</tr>
<tr>
<td>GentleMax Family of Laser Systems</td>
<td>Candela</td>
<td>2014</td>
</tr>
<tr>
<td>Nordlys</td>
<td>Ellipse A/S</td>
<td>2016</td>
</tr>
<tr>
<td>Dual wavelength Nd:YAG 1064-nm and 532-nm laser system</td>
<td>Q-Clear™ Light Age</td>
<td>2011</td>
</tr>
</tbody>
</table>

Nd:YAG 1064-nm laser systems (FDA product code: GEX); dual wavelength Nd:YAG 1064-nm and 532-nm laser system (FDA product code: PDX).

**Rationale**

This evidence review was originally created in May 2013 with a search of the MEDLINE database. The most recent update with literature review covered the period through November 8, 2016.

The main question for this evidence review is whether laser treatment is an efficacious treatment for onychomycosis and whether it is at least as effective as alternatives. Randomized controlled trials (RCTs) with appropriate comparison groups are the best study design to evaluate the effectiveness of laser treatment for onychomycosis. The most important outcomes for onychomycosis treatments are clinical cure of onychomycosis (ie, complete clearing without recurrence) and
mycological cure. Other useful outcomes would be symptoms and functional measures related to onychomycosis. Partial healing and accelerated nail growth are intermediate outcomes that may or may not be associated with the ultimate cure rate. The most appropriate comparator interventions are sham laser treatment, if patient blinding is considered necessary, and best alternative care (e.g., topical antifungals).

**Laser treatment for onychomycosis**

**Systematic Reviews**
A 2014 systematic review by Bristow et al identified 12 published studies on laser treatment for onychomycosis. Two were RCTs, 4 were nonrandomized comparative studies, and the other 6 were case series. Reviewers did not pool study findings but concluded that the evidence was limited and of poor methodologic quality. Representative RCTs with the largest sample sizes that compared laser treatment to placebo or to a different intervention are described next.

**Randomized Controlled Trials**
Karsai et al (2016) reported on a prospective randomized pilot trial with blinded outcome assessment comparing laser treatment (short-pulsed 1064-nm-ND:YAG laser) with control (no laser treatment) in 20 patients with 82 mycotic toenails. All patients received treatment with amorolfine cream over the soles of the feet, their intertriginous areas, and the skin directly surrounding the nails. Patients in the laser group received 4 treatments at intervals of 4 to 6 weeks. The trial’s primary end point (the proportion of nails with mycological remission) was not achieved in either group after 12 months. The study’s secondary end point was the clinical appearance of the nails using the Onychomycosis Severity Index (OSI), which was assessed by 2 independent blinded investigators. There were no differences in OSI scores at baseline or at 12-month follow-up. The OSI score worsened by a mean of 2.0 points in the treatment group compared with 3.6 points in the control group (between group change, 1.6 points; 95% confidence interval, -0.7 to 3.9; p=0.553).

In another RCT, Kim et al (2016) compared 1064-nm Nd:YAG laser therapy alone (n=19) to laser with topical antifungal therapy (n=18) and topical antifungal therapy (n=19) among 56 patients (in the final group; original N enrolled not specified). Topical antifungal therapy included naftifine spray. Laser sessions were repeated at 4-week intervals for 12 weeks. Clinical response rates at 12 weeks were 70.9% in the laser only group, 73.2% in the laser plus topical group, and 14.9% in the topical group (p<0.05 for difference vs topical-only group). Cure rates at 24 weeks were 15.2% in the laser only group, 22.5% of the laser plus topical group, and 4.5% of the topical group (p<0.05 for difference vs topical-only group). There was no mention of blinded outcome assessment.

In 2015, El-Tatawy et al in Egypt reported on 40 patients with toenail onychomycosis randomized to 4 sessions of treatment with a 1064-nm Nd:YAG laser (n=20) or topical terbinafine twice daily for 6 months (n=20). The laser was
a Dualis SP device (Fotona, Slovenia). The clinical efficacy outcome measure categorized patients into those with marked improvement (>75%), moderate improvement (50%-75%), mild improvement (25%-50%), or no improvement (<25%). The authors did not state that outcome assessment was blinded. At the end of the 6 months, 100% of patients in the laser group and none in the medication group showed marked improvement (p<0.002). In the medication group, 8 patients had mild improvement, 2 had moderate improvement, and 10 had no improvement. Lack of blinding could have introduced bias in the clinical assessment of patients.

A 2014 trial by Xu et al in China randomized 53 patients with toenail onychomycosis to 1 of 3 treatment groups: daily oral terbinafine 250 mg, weekly long-pulsed 1064-nm Nd:YAG laser (Luminis One), or a combination of the 2 therapies. The medication-only group included 16 patients with 30 infected nails, the laser group included 18 patients with 31 infected nails, and the combination treatment group included 16 patients with 29 infected nails. Analysis was done on a per-nail basis. All patients completed the 24-month follow-up. At this final evaluation point, the clinical clearance rate (defined as ≤5% nail plate involvement in onychomycosis) was 22 (73.3%) of 30 nails in the medication-only group, 20 (64.5%) of 31 nails in the laser group, and 28 (96.6%) of 29 nails in the combination treatment group. The rate was significantly higher in the combined treatment group than in either treatment alone; clinical clearance in the medication versus laser group did not differ significantly. Findings were similar for the mycological clearance rate. A limitation of this study was its reporting of outcomes on a per-nail basis, which did not account for correlated measurements.

In 2010, an industry-sponsored study by Landsman et al, used a dual-wavelength near-infrared diode laser that has not been cleared by the U.S. Food and Drug Administration for treatment of onychomycosis. The study included 36 patients with mycologically confirmed onychomycosis. Patients were randomized to actual laser treatment (n=26) or sham treatment (n=10). The sham treatment group received the same number of sessions, but laser power was set to zero. Thirty-four (94%) of 36 patients completed the study. These 34 patients had a total of 59 toes treated with an active or sham laser. Thirty-seven toes met all of the clinical eligibility criteria (26 in the active treatment group, 11 in the control group).

The primary study outcomes were the proportion of patients who had at least 3 mm of clear nail growth and who attained a negative mycological finding. As assessed by the blinded expert panel, at 180 days, 17 (65%) of 26 toes in the active treatment group and 1 (9%) of 11 in the control group attained at least 3 mm of clear lineal nail growth. The difference between groups was statistically significant, favoring the active treatment group (p=0.011). Moreover, 10 (39%) of 26 toes in the active treatment group and 1 (9%) of 11 in the control group had both a negative mycological culture and at least 3 mm of clear nail growth at 180 days; the difference between groups was not statistically significant (p=0.119).

In the subjective clinical visual assessment of improvement at 180 days, investigators judged 5 (19%) of 26 toes in the active treatment group and 2
(18%) of 11 in the control group to be markedly improved. No toes were judged to be completely cleared. Reviewing photographs, the expert panel judged 1 (4%) toe in the active treatment group and 2 (18%) toes in the control group to be markedly improved and 1 toe (4%) in the active treatment group to be completely cleared. (Statistical comparisons of the treatment vs sham group were not reported for the visual assessment outcome.)

In 2012, Landsman and Robbins reported 270-day results in 36 of 40 treated toes. This included clinically eligible toes as well as companion toes.) When photographs of 34 toes were evaluated, 35% were considered to have continued improvement, 38% were considered not to have changed since 180 days, and 20% were considered to have worsened. Authors did not report 270-day findings in patients assigned to the sham control group.

Limitations of the 2 Landsman studies included the intermediate outcome measures used (eg, 3 mm of clear lineal nail growth), which are of uncertain clinical significance. In addition, investigators randomized patients to a treatment group and a control group, yet presented their findings on a per-nail basis, which did not account for correlated measurements. Three (9%) of the 34 patients evaluated at 180 days contributed data from 2 toes to the analysis.

Summary of Evidence
For individuals who have onychomycosis who receive treatment with laser therapy, the evidence includes small randomized controlled trials (RCTs). Relevant outcomes are symptoms, change in disease status, medication use, and treatment-related morbidity. Some of the available RCTs have reported improvements in clinical outcomes with laser treatment, but these trials have mixed results and methodologic limitations. Clinical and mycological outcomes sometimes differed in the trials, which may be due in part to lack of consistent blinding of outcome assessment. The published evidence to date does not permit determining whether laser treatment improves health outcomes in patients with onychomycosis. Additional well-designed, adequately powered, and well-conducted RCTs are needed. The evidence is insufficient to determine the effects of the technology on health outcomes.

Supplemental Information

Practice Guidelines and Position Statements

British Association of Dermatologists
In 2014, the British Association of Dermatologists (BAD) issued guidelines on the management of onychomycosis. Due to the limited nature of the evidence, BAD concluded that “lasers are showing promising results in the treatment of onychomycosis, but recommendations cannot be made at this stage” (level of evidence 1-).

U.S. Preventive Services Task Force Recommendations
Not applicable.
Medicare National Coverage
There is no national coverage determination (NCD). In the absence of an NCD, coverage decisions are left to the discretion of local Medicare carriers.

Ongoing and Unpublished Clinical Trials
Some currently ongoing and unpublished trials that might influence this review are listed in Table 3.

Table 3. Summary of Key Trials

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ongoing</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT02019446</td>
<td>Laser Treatment for Onychomycosis in Diabetes</td>
<td>60</td>
<td>Jan 2017</td>
</tr>
<tr>
<td>NCT02812043</td>
<td>Comparison Between Long-pulsed Nd:YAG, Amorolfine and Combination Treatment in Treating Non-dermatophyte Onychomycosis</td>
<td>60</td>
<td>Apr 2017</td>
</tr>
<tr>
<td>NCT01996995</td>
<td>Laser Therapy for Onychomycosis in Patients with Diabetes at Risk for Diabetic Foot Complications (LASER-1)</td>
<td>64</td>
<td>Jul 2017</td>
</tr>
<tr>
<td><strong>Unpublished</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT01915355</td>
<td>Pulsed Dye Laser Treatment of Onychomycosis</td>
<td>11</td>
<td>Jul 2015 (completed)</td>
</tr>
<tr>
<td>NCT02588599a</td>
<td>A Retrospective Analysis of the Effects of Low Level Laser Therapy on Toenail Onychomycosis</td>
<td>54</td>
<td>Oct 2015 (completed)</td>
</tr>
</tbody>
</table>

NCT: national clinical trial.
a Denotes industry-sponsored or cosponsored trial.

References


**Billing Coding/Physician Documentation Information**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>17999</td>
<td>Unlisted procedure, skin, mucous membrane and subcutaneous tissue</td>
</tr>
<tr>
<td>96999</td>
<td>Unlisted special dermatological service or procedure</td>
</tr>
</tbody>
</table>

**ICD10 Codes**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>B35.1</td>
<td>Dermatophytosis - Tinea unguium (includes onychomycosis)</td>
</tr>
</tbody>
</table>

**Additional Policy Key Words**

N/A

**Policy Implementation/Update Information**

<table>
<thead>
<tr>
<th>Date</th>
<th>Change Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>11/1/15</td>
<td>New Policy; considered investigational.</td>
</tr>
<tr>
<td>5/1/16</td>
<td>No policy statement changes.</td>
</tr>
<tr>
<td>11/1/16</td>
<td>No policy statement changes.</td>
</tr>
<tr>
<td>5/1/17</td>
<td>No policy statement changes.</td>
</tr>
</tbody>
</table>

State and Federal mandates and health plan contract language, including specific provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The medical policies contained herein are for informational purposes. The medical policies do not constitute medical advice or medical care. Treating health care providers are independent contractors and are neither employees nor agents Blue KC and are solely responsible for diagnosis, treatment and medical advice. No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, photocopying, or otherwise, without permission from Blue KC.